VKTX vs. MDGL

In the year-to-date period, VKTX achieves a -31.54% return, which is significantly lower than MDGL's -4.51% return. Over the past 10 years, VKTX has underperformed MDGL with an annualized return of 11.87%, while MDGL has yielded a comparatively higher 13.84% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Viking Therapeutics, Inc. (VKTX) and Madrigal Pharmaceuticals, Inc. (MDGL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current VKTX Sharpe Ratio is -0.78, which is lower than the MDGL Sharpe Ratio of 0.71. The chart below compares the historical Sharpe Ratios of VKTX and MDGL, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither VKTX nor MDGL has paid dividends to shareholders.

The maximum VKTX drawdown since its inception was -90.41%, smaller than the maximum MDGL drawdown of -98.40%. Use the drawdown chart below to compare losses from any high point for VKTX and MDGL. For additional features, visit the drawdowns tool.

Viking Therapeutics, Inc. (VKTX) has a higher volatility of 21.06% compared to Madrigal Pharmaceuticals, Inc. (MDGL) at 11.63%. This indicates that VKTX's price experiences larger fluctuations and is considered to be riskier than MDGL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Viking Therapeutics, Inc. and Madrigal Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.